Neue Optionen zur Intensivierung der lipidsenkenden Therapie View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2022-04-29

AUTHORS

Andrea Baessler, Marcus Fischer

ABSTRACT

Epidemiological, randomized, controlled, clinical and genetic studies confirm that low-density lipoprotein cholesterol (LDL-C) is a causative factor for atherosclerotic diseases. The current European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) guidelines on the management of dyslipidemia recommend a target LDL-C < 55 mg/dl and at least a 50% reduction in baseline LDL‑C for high-risk patients; however, these target values are often not achieved in routine clinical practice, as shown by recent cross-sectional data from EUROASPIRE or DaVinci. Therefore, combination treatment is recommended, which, as with treatment of blood pressure, can improve the success of treatment. Bempedoic acid is a new substance, which is suitable for combination treatment and represents an alternative particularly for patients with statin-associated muscular symptoms. Bempedoic acid reduces LDL‑C by approximately 25% in statin-naïve patients and by some 18% in addition to statins. In a fixed doses combination with ezetimibe, bempedoic acid can lower LDL‑C by up to 45% in statin-naïve patients and by 38% (placebo-corrected) in addition to statins. Bempedoic acid is generally very well tolerated: however, it can lead to a reversible increase in uric acid. Occasionally, a slight decrease in hemoglobin has been documented. Therefore, it is recommended that not only changes in lipid levels but also uric acid and hematological parameters should be monitored in the first 3 months. More... »

PAGES

212-219

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00059-022-05111-z

DOI

http://dx.doi.org/10.1007/s00059-022-05111-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1147504981

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/35486131


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anticholesteremic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Atherosclerosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cholesterol, LDL", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross-Sectional Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dicarboxylic Acids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fatty Acids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Uric Acid", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Klinik und Poliklinik f\u00fcr Innere Medizin II, Universit\u00e4tsklinikum Regensburg, Franz-Josef-Strau\u00df-Allee\u00a011, 93053, Regensburg, Deutschland", 
          "id": "http://www.grid.ac/institutes/grid.411941.8", 
          "name": [
            "Klinik und Poliklinik f\u00fcr Innere Medizin II, Universit\u00e4tsklinikum Regensburg, Franz-Josef-Strau\u00df-Allee\u00a011, 93053, Regensburg, Deutschland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baessler", 
        "givenName": "Andrea", 
        "id": "sg:person.01136526353.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136526353.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Klinik f\u00fcr Kardiologie, Angiologie, Pneumologie und Intensivmedizin, Goldberg-Klinik Kelheim, Kelheim, Deutschland", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Klinik und Poliklinik f\u00fcr Innere Medizin II, Universit\u00e4tsklinikum Regensburg, Franz-Josef-Strau\u00df-Allee\u00a011, 93053, Regensburg, Deutschland", 
            "Klinik f\u00fcr Kardiologie, Angiologie, Pneumologie und Intensivmedizin, Goldberg-Klinik Kelheim, Kelheim, Deutschland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fischer", 
        "givenName": "Marcus", 
        "id": "sg:person.013735664232.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013735664232.23"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10557-021-07147-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1136928365", 
          "https://doi.org/10.1007/s10557-021-07147-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40261-021-01075-w", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1140638670", 
          "https://doi.org/10.1007/s40261-021-01075-w"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00392-020-01740-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1130966110", 
          "https://doi.org/10.1007/s00392-020-01740-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11906-020-01069-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1130369774", 
          "https://doi.org/10.1007/s11906-020-01069-7"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2022-04-29", 
    "datePublishedReg": "2022-04-29", 
    "description": "Epidemiological, randomized, controlled, clinical and genetic studies confirm that low-density lipoprotein cholesterol (LDL-C) is a\u00a0causative factor for atherosclerotic diseases. The current European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) guidelines on the management of dyslipidemia recommend a\u00a0target LDL-C\u202f<\u200955\u202fmg/dl and at least a\u00a050% reduction in baseline LDL\u2011C for high-risk patients; however, these target values are often not achieved in routine clinical practice, as shown by recent cross-sectional data from EUROASPIRE or DaVinci. Therefore, combination treatment is recommended, which, as with treatment of blood pressure, can improve the success of treatment. Bempedoic acid is a\u00a0new substance, which is suitable for combination treatment and represents an alternative particularly for patients with statin-associated muscular symptoms. Bempedoic acid reduces LDL\u2011C by approximately 25% in statin-na\u00efve patients and by some 18% in addition to statins. In a fixed doses combination with ezetimibe, bempedoic acid can lower LDL\u2011C by up to 45% in statin-na\u00efve patients and by 38% (placebo-corrected) in addition to statins. Bempedoic acid is generally very well tolerated: however, it can lead to a\u00a0reversible increase in uric acid. Occasionally, a\u00a0slight decrease in hemoglobin has been documented. Therefore, it is recommended that not only changes in lipid levels but also uric acid and hematological parameters should be monitored in the first 3\u00a0months.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00059-022-05111-z", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1087175", 
        "issn": [
          "0340-9937", 
          "1615-6692"
        ], 
        "name": "Herz", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "47"
      }
    ], 
    "keywords": [
      "statin-na\u00efve patients", 
      "bempedoic acid", 
      "combination treatment", 
      "European Atherosclerosis Society guidelines", 
      "low-density lipoprotein cholesterol", 
      "Atherosclerosis Society guidelines", 
      "management of dyslipidemia", 
      "high-risk patients", 
      "routine clinical practice", 
      "uric acid", 
      "current European Society", 
      "success of treatment", 
      "target LDL", 
      "baseline LDL", 
      "lipoprotein cholesterol", 
      "blood pressure", 
      "muscular symptoms", 
      "atherosclerotic disease", 
      "Society guidelines", 
      "lipid levels", 
      "clinical practice", 
      "hematological parameters", 
      "patients", 
      "LDL", 
      "statins", 
      "causative factors", 
      "European Society", 
      "cross-sectional data", 
      "reversible increase", 
      "treatment", 
      "recent cross-sectional data", 
      "EUROASPIRE", 
      "dyslipidemia", 
      "new substances", 
      "Therapie", 
      "ezetimibe", 
      "symptoms", 
      "dl", 
      "disease", 
      "cholesterol", 
      "cardiology", 
      "genetic studies", 
      "months", 
      "hemoglobin", 
      "slight decrease", 
      "acid", 
      "guidelines", 
      "management", 
      "factors", 
      "levels", 
      "addition", 
      "decrease", 
      "study", 
      "substances", 
      "increase", 
      "reduction", 
      "daVinci", 
      "changes", 
      "pressure", 
      "practice", 
      "target values", 
      "combination", 
      "data", 
      "success", 
      "alternative", 
      "values", 
      "society", 
      "parameters"
    ], 
    "name": "Neue Optionen zur Intensivierung der lipidsenkenden Therapie", 
    "pagination": "212-219", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1147504981"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00059-022-05111-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "35486131"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00059-022-05111-z", 
      "https://app.dimensions.ai/details/publication/pub.1147504981"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:07", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_941.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00059-022-05111-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05111-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05111-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05111-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00059-022-05111-z'


 

This table displays all metadata directly associated to this object as RDF triples.

192 TRIPLES      21 PREDICATES      106 URIs      94 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00059-022-05111-z schema:about N0201ca62ab6e4dd49cead769d19d2644
2 N06e2db5128f8402eb31acca4c4827d42
3 N10ee8558664b44cca011428c2d1c4f5b
4 N1e6653edc3e046ad93019eec280914b6
5 N958898c303c04be3b2078a08e3ff7972
6 Na16ad53a106149a994178cd885ff7234
7 Naf3ca6c2b00147069f92d082fe204e66
8 Ndd3beec7975347519fe2326f8b5caf62
9 Nf50ea06975334800b9ef455a459eaea6
10 anzsrc-for:11
11 anzsrc-for:1102
12 schema:author N1548e77fa23943deba86dd0061f371e6
13 schema:citation sg:pub.10.1007/s00392-020-01740-8
14 sg:pub.10.1007/s10557-021-07147-5
15 sg:pub.10.1007/s11906-020-01069-7
16 sg:pub.10.1007/s40261-021-01075-w
17 schema:datePublished 2022-04-29
18 schema:datePublishedReg 2022-04-29
19 schema:description Epidemiological, randomized, controlled, clinical and genetic studies confirm that low-density lipoprotein cholesterol (LDL-C) is a causative factor for atherosclerotic diseases. The current European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) guidelines on the management of dyslipidemia recommend a target LDL-C < 55 mg/dl and at least a 50% reduction in baseline LDL‑C for high-risk patients; however, these target values are often not achieved in routine clinical practice, as shown by recent cross-sectional data from EUROASPIRE or DaVinci. Therefore, combination treatment is recommended, which, as with treatment of blood pressure, can improve the success of treatment. Bempedoic acid is a new substance, which is suitable for combination treatment and represents an alternative particularly for patients with statin-associated muscular symptoms. Bempedoic acid reduces LDL‑C by approximately 25% in statin-naïve patients and by some 18% in addition to statins. In a fixed doses combination with ezetimibe, bempedoic acid can lower LDL‑C by up to 45% in statin-naïve patients and by 38% (placebo-corrected) in addition to statins. Bempedoic acid is generally very well tolerated: however, it can lead to a reversible increase in uric acid. Occasionally, a slight decrease in hemoglobin has been documented. Therefore, it is recommended that not only changes in lipid levels but also uric acid and hematological parameters should be monitored in the first 3 months.
20 schema:genre article
21 schema:isAccessibleForFree false
22 schema:isPartOf N7c5b08c7a8dc43afa30efab6e031df33
23 Nd6d86f398df846c89249377d3b0b9b94
24 sg:journal.1087175
25 schema:keywords Atherosclerosis Society guidelines
26 EUROASPIRE
27 European Atherosclerosis Society guidelines
28 European Society
29 LDL
30 Society guidelines
31 Therapie
32 acid
33 addition
34 alternative
35 atherosclerotic disease
36 baseline LDL
37 bempedoic acid
38 blood pressure
39 cardiology
40 causative factors
41 changes
42 cholesterol
43 clinical practice
44 combination
45 combination treatment
46 cross-sectional data
47 current European Society
48 daVinci
49 data
50 decrease
51 disease
52 dl
53 dyslipidemia
54 ezetimibe
55 factors
56 genetic studies
57 guidelines
58 hematological parameters
59 hemoglobin
60 high-risk patients
61 increase
62 levels
63 lipid levels
64 lipoprotein cholesterol
65 low-density lipoprotein cholesterol
66 management
67 management of dyslipidemia
68 months
69 muscular symptoms
70 new substances
71 parameters
72 patients
73 practice
74 pressure
75 recent cross-sectional data
76 reduction
77 reversible increase
78 routine clinical practice
79 slight decrease
80 society
81 statin-naïve patients
82 statins
83 study
84 substances
85 success
86 success of treatment
87 symptoms
88 target LDL
89 target values
90 treatment
91 uric acid
92 values
93 schema:name Neue Optionen zur Intensivierung der lipidsenkenden Therapie
94 schema:pagination 212-219
95 schema:productId N5eb5af4d4f0e46d2b1cd8ce74ef4fde0
96 N904ff1ff4f974b008686aff3571c5a1f
97 Ne0e2918b1bcb43f2bf09d0fe48b040f7
98 schema:sameAs https://app.dimensions.ai/details/publication/pub.1147504981
99 https://doi.org/10.1007/s00059-022-05111-z
100 schema:sdDatePublished 2022-09-02T16:07
101 schema:sdLicense https://scigraph.springernature.com/explorer/license/
102 schema:sdPublisher N0afab652f1cb4ab49642bbf812b4ceb3
103 schema:url https://doi.org/10.1007/s00059-022-05111-z
104 sgo:license sg:explorer/license/
105 sgo:sdDataset articles
106 rdf:type schema:ScholarlyArticle
107 N0201ca62ab6e4dd49cead769d19d2644 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Cholesterol, LDL
109 rdf:type schema:DefinedTerm
110 N06e2db5128f8402eb31acca4c4827d42 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Cross-Sectional Studies
112 rdf:type schema:DefinedTerm
113 N0afab652f1cb4ab49642bbf812b4ceb3 schema:name Springer Nature - SN SciGraph project
114 rdf:type schema:Organization
115 N0eb56ae924e740738757bfca4b145701 rdf:first sg:person.013735664232.23
116 rdf:rest rdf:nil
117 N10ee8558664b44cca011428c2d1c4f5b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Anticholesteremic Agents
119 rdf:type schema:DefinedTerm
120 N1548e77fa23943deba86dd0061f371e6 rdf:first sg:person.01136526353.04
121 rdf:rest N0eb56ae924e740738757bfca4b145701
122 N1e6653edc3e046ad93019eec280914b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Atherosclerosis
124 rdf:type schema:DefinedTerm
125 N5eb5af4d4f0e46d2b1cd8ce74ef4fde0 schema:name dimensions_id
126 schema:value pub.1147504981
127 rdf:type schema:PropertyValue
128 N7c5b08c7a8dc43afa30efab6e031df33 schema:issueNumber 3
129 rdf:type schema:PublicationIssue
130 N904ff1ff4f974b008686aff3571c5a1f schema:name doi
131 schema:value 10.1007/s00059-022-05111-z
132 rdf:type schema:PropertyValue
133 N958898c303c04be3b2078a08e3ff7972 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Hydroxymethylglutaryl-CoA Reductase Inhibitors
135 rdf:type schema:DefinedTerm
136 Na16ad53a106149a994178cd885ff7234 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Fatty Acids
138 rdf:type schema:DefinedTerm
139 Naf3ca6c2b00147069f92d082fe204e66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Uric Acid
141 rdf:type schema:DefinedTerm
142 Nd6d86f398df846c89249377d3b0b9b94 schema:volumeNumber 47
143 rdf:type schema:PublicationVolume
144 Ndd3beec7975347519fe2326f8b5caf62 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Dicarboxylic Acids
146 rdf:type schema:DefinedTerm
147 Ne0e2918b1bcb43f2bf09d0fe48b040f7 schema:name pubmed_id
148 schema:value 35486131
149 rdf:type schema:PropertyValue
150 Nf50ea06975334800b9ef455a459eaea6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Humans
152 rdf:type schema:DefinedTerm
153 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
154 schema:name Medical and Health Sciences
155 rdf:type schema:DefinedTerm
156 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
157 schema:name Cardiorespiratory Medicine and Haematology
158 rdf:type schema:DefinedTerm
159 sg:journal.1087175 schema:issn 0340-9937
160 1615-6692
161 schema:name Herz
162 schema:publisher Springer Nature
163 rdf:type schema:Periodical
164 sg:person.01136526353.04 schema:affiliation grid-institutes:grid.411941.8
165 schema:familyName Baessler
166 schema:givenName Andrea
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136526353.04
168 rdf:type schema:Person
169 sg:person.013735664232.23 schema:affiliation grid-institutes:None
170 schema:familyName Fischer
171 schema:givenName Marcus
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013735664232.23
173 rdf:type schema:Person
174 sg:pub.10.1007/s00392-020-01740-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1130966110
175 https://doi.org/10.1007/s00392-020-01740-8
176 rdf:type schema:CreativeWork
177 sg:pub.10.1007/s10557-021-07147-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1136928365
178 https://doi.org/10.1007/s10557-021-07147-5
179 rdf:type schema:CreativeWork
180 sg:pub.10.1007/s11906-020-01069-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1130369774
181 https://doi.org/10.1007/s11906-020-01069-7
182 rdf:type schema:CreativeWork
183 sg:pub.10.1007/s40261-021-01075-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1140638670
184 https://doi.org/10.1007/s40261-021-01075-w
185 rdf:type schema:CreativeWork
186 grid-institutes:None schema:alternateName Klinik für Kardiologie, Angiologie, Pneumologie und Intensivmedizin, Goldberg-Klinik Kelheim, Kelheim, Deutschland
187 schema:name Klinik für Kardiologie, Angiologie, Pneumologie und Intensivmedizin, Goldberg-Klinik Kelheim, Kelheim, Deutschland
188 Klinik und Poliklinik für Innere Medizin II, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Deutschland
189 rdf:type schema:Organization
190 grid-institutes:grid.411941.8 schema:alternateName Klinik und Poliklinik für Innere Medizin II, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Deutschland
191 schema:name Klinik und Poliklinik für Innere Medizin II, Universitätsklinikum Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Deutschland
192 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...